Photocure ASA
OSE:PHO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
48.05
70.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Photocure ASA
Photocure ASA
Cost of Revenue
Photocure ASA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Cost of Revenue
-kr28.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-15%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Cost of Revenue
-kr167.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Cost of Revenue
-kr325.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-9%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Cost of Revenue?
Cost of Revenue
-28.1m
NOK
Based on the financial report for Jun 30, 2024, Photocure ASA's Cost of Revenue amounts to -28.1m NOK.
What is Photocure ASA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-15%
Over the last year, the Cost of Revenue growth was -14%. The average annual Cost of Revenue growth rates for Photocure ASA have been -9% over the past three years , -8% over the past five years , and -15% over the past ten years .
You don't have any saved screeners yet
